Pharmacotherapeutic management of trigeminal neuropathic pain: an update

References

• Smith JH, Cutrer FM. Numbness matters: a clinical review of trigeminal neuropathy. Cephalalgia. 2011 Jul;31(10):1131–1144.
   PubMedGoogle Scholar
• Di Stefano G, Truini A, Cruccu G. Current and Innovative Pharmacological Options to Treat Typical and Atypical Trigeminal Neuralgia. Drugs. 2018 Sep;78(14):1433–1442.
   PubMedGoogle Scholar
• Maarbjerg S, Gozalov A, Olesen J, et al. Trigeminal neuralgia–a prospective systematic study of clinical characteristics in 158 patients. Headache. 2014 Nov-Dec;54(10):1574–1582.
   PubMed Web of Science ®Google Scholar
• Maarbjerg S, Gozalov A, Olesen J, et al. Concomitant persistent pain in classical trigeminal neuralgia–evidence for different subtypes. Headache. 2014 Jul-Aug;54(7):1173–1183.
   PubMed Web of Science ®Google Scholar
• Kotecha M, Cheshire WP, Finnigan H, et al. Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia. J Pain Res. 2020;13:1601–1609.
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Maarbjerg S, Truini A. Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options. J Headache Pain. 2019 Feb 19; 20(1):20.
   PubMedGoogle Scholar
• Cruccu G, Biasiotta A, Di Rezze S, et al. Trigeminal neuralgia and pain related to multiple sclerosis. Pain. 2009 Jun;143(3):186–191.
   PubMed Web of Science ®Google Scholar
• Nurmikko TJ. Pathophysiology of MS-related trigeminal neuralgia. Pain. 2009 Jun;143(3):165–166.
   PubMedGoogle Scholar
• Truini A, Prosperini L, Calistri V, et al. A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis. Neurology. 2016 May 31;86(22):2094–2099.
   PubMedGoogle Scholar
• Cruccu G, Finnerup NB, Jensen TS, et al. Trigeminal neuralgia: New classification and diagnostic grading for practice and research. Neurology. 2016 Jul 12; 87(2):220–228.
   PubMed Web of Science ®Google Scholar
• Devor M, Amir R, Rappaport ZH. Pathophysiology of trigeminal neuralgia: the ignition hypothesis. Clin J Pain. 2002 Jan-Feb;18(1):4–13.
   PubMed Web of Science ®Google Scholar
• Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain. 2002;6(SA):61–68.
   PubMedGoogle Scholar
• Baad-Hansen L, Benoliel R. Neuropathic orofacial pain: Facts and fiction. Cephalalgia. 2017 Jun;37(7):670–679.
   PubMed Web of Science ®Google Scholar
• Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019 Jun;26(6):831–849.
   PubMed Web of Science ®Google Scholar
• Cruccu G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008 Oct;15(10):1013–1028.
   PubMed Web of Science ®Google Scholar
• Nurmikko TJ, Eldridge PR. Trigeminal neuralgia–pathophysiology, diagnosis and current treatment. Br J Anaesth. 2001 Jul;87(1):117–132.
   PubMedGoogle Scholar
• Nardi A, Damann N, Hertrampf T, et al. Advances in Targeting Voltage-Gated Sodium Channels with Small Molecules.ChemMedChem. 2012;7(10):1712–1740.
   PubMed Web of Science ®Google Scholar
• de Lera Ruiz M, Kraus RL. Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. J Med Chem. 2015 Sep 24;58(18):7093–7118.
   PubMed Web of Science ®Google Scholar
• Beydoun A. Clinical use of tricyclic anticonvulsants in painful neuropathies and bipolar disorders. Epilepsy Behav. 2002 Jun;3(3s):S18–s22.
   PubMedGoogle Scholar
• Beydoun A. Safety and efficacy of oxcarbazepine: results of randomized, double-blind trials. Pharmacotherapy. 2000 Aug;20(8 Pt 2):152s–58s.
   PubMed Web of Science ®Google Scholar
• Di Stefano G, La Cesa S, Truini A, et al. Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. J Headache Pain. 2014 Jun 9;15(1):34.
   PubMedGoogle Scholar
• Tegretol, Carabamazepine Prescribing Information. 2009 [cited 2022 January 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016608s101,018281s048lbl.pdf
   Google Scholar
• Highlight of Prescribing Information: Trileptal. 2017 [cited 2022 January 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021014s036lbl.pdf
   Google Scholar
• Rasmussen P, Riishede J. Facial pain treated with carbamazepin (Tegretol). Acta Neurol Scand. 1970;46(4):385–408.
   PubMedGoogle Scholar
• Taylor JC, Brauer S, Espir ML. Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J. 1981 Jan;57(663):16–18.
   PubMed Web of Science ®Google Scholar
• Kutluay E, McCague K, D’Souza J, et al. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav. 2003 Apr;4(2):175–180.
   PubMed Web of Science ®Google Scholar
• Shaikh S, Yaacob HB, Abd Rahman RB. Lamotrigine for trigeminal neuralgia: efficacy and safety in comparison with carbamazepine. J Chin Med Assoc. 2011 Jun;74(6):243–249.
   PubMedGoogle Scholar
• Yuan M, Zhou HY, Xiao ZL, et al. Efficacy and Safety of Gabapentin vs. Carbamazepine in the Treatment of Trigeminal Neuralgia: A Meta-Analysis. Pain Pract. 2016 Nov;16(8):1083–1091.
   PubMed Web of Science ®Google Scholar
• Obermann M, Yoon MS, Sensen K, et al. Efficacy of pregabalin in the treatment of trigeminal neuralgia. Cephalalgia. 2008 Feb;28(2):174–181.
   PubMed Web of Science ®Google Scholar
• Goa KL, Sorkin EM. Gabapentin. Drugs 1993;46(3):409–427.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Gangemi P, Perucca P, et al. The adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials.Epilepsia. 2011;52(4):826–836.
   PubMed Web of Science ®Google Scholar
• Evoy KE, Morrison MD, Saklad SR. Abuse and Misuse of Pregabalin and Gabapentin. Drugs. 2017 Mar;77(4):403–426.
   PubMed Web of Science ®Google Scholar
• Chincholkar M. Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. Br J Anaesth. 2018 Jun;120(6):1315–1334.
   PubMed Web of Science ®Google Scholar
• Guo B-L, Zheng C-X, Sui B-D, et al. A closer look to botulinum neurotoxin type A-induced analgesia. Toxicon. 2013;71:134–139.
   PubMed Web of Science ®Google Scholar
• Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol. 1984 Mar;15(3):240–244.
   PubMed Web of Science ®Google Scholar
• Fromm GH, Terrence CF. Comparison of L-baclofen and racemic baclofen in trigeminal neuralgia. Neurology. 1987 Nov;37(11):1725–1728.
   PubMed Web of Science ®Google Scholar
• Liang YC, Huang CC, Hsu KS. Therapeutic potential of cannabinoids in trigeminal neuralgia. Curr Drug Targets CNS Neurol Disord. 2004 Dec;3(6):507–514.
   PubMedGoogle Scholar
• Fiani B, Sarhadi KJ, Soula M, et al. Current application of cannabidiol (CBD) in the management and treatment of neurological disorders. Neurol Sci. 2020 Nov;41(11):3085–3098.
   PubMedGoogle Scholar
• McDonough P, McKenna JP, McCreary C, et al. Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. Int J Biochem Cell Biol. 2014 Oct;55:72–78.
   PubMed Web of Science ®Google Scholar
• Gajofatto A. Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis. Mult Scler Relat Disord. 2016 Jul;8:64–65.
   PubMed Web of Science ®Google Scholar
• Ashton JC, Milligan ED. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr opin invest drugs (London, England: 2000). 2008;9(1):65–75.
   PubMedGoogle Scholar
• Alcántara Montero A, Sánchez Carnerero CI. Eslicarbazepine acetate for neuropathic pain, headache, and cranial neuralgia: Evidence and experience. Neurologia (Engl Ed). 2019 Jul-Aug;34(6): 386–395.
   PubMedGoogle Scholar
• Alcántara Montero A, Sánchez Carnerero CI, Comment on a paper by Sanchez-Larsen A, et al. Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia. Eur J Pain. 2018 Jul;22(6):1188–1189.
   PubMedGoogle Scholar
• Sanchez-Larsen A, Sopelana D, Diaz-Maroto I, et al. Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia. Eur J Pain. 2018 Jul;22(6):1080–1087.
   PubMed Web of Science ®Google Scholar
• Howard P, Remi J, Remi C, et al. Levetiracetam. J Pain Symptom Manage. 2018 Oct;56(4):645–649.
   PubMedGoogle Scholar
• Malawska B, Kulig K. Brivaracetam: a new drug in development for epilepsy and neuropathic pain. Expert Opin Investig Drugs. 2008 Mar;17(3):361–369.
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Moore RA, et al. Levetiracetam for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;2014(7):CD010943.
   Google Scholar
• Jorns TP, Johnston A, Zakrzewska JM. Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia. Eur J Neurol. 2009 Jun;16(6):740–744.
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD, Pantes GV, Avramidis TG, et al. An observational trial to investigate the efficacy and tolerability of levetiracetam in trigeminal neuralgia. Headache. 2010 Sep;50(8):1371–1377.
   PubMedGoogle Scholar
• Ruetsch YA, Böni T, Borgeat A. From cocaine to ropivacaine: the history of local anesthetic drugs. Curr Top Med Chem. 2001 Aug;1(3):175–182.
   PubMedGoogle Scholar
• Kanai A, Suzuki A, Kobayashi M, et al. Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. Br J Anaesth. 2006 Oct;97(4):559–563.
   PubMed Web of Science ®Google Scholar
• Niki Y, Kanai A, Hoshi K, et al. Immediate analgesic effect of 8% lidocaine applied to the oral mucosa in patients with trigeminal neuralgia. Pain medicine (Malden, Mass). 2014 May;15(5):826–831.
   PubMedGoogle Scholar
• Pfau G, Brinkers M, Treuheit T, et al. Misoprostol as a Therapeutic Option for Trigeminal Neuralgia in Patients with Multiple Sclerosis. Pain Med. 2012;13(10):1377–1378.
   PubMedGoogle Scholar
• DMKG study group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol. 2003 May;250(5):542–545.
   PubMedGoogle Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010 Sep;17(9):1113–e88.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain–United States, 2016. Jama. 2016 Apr 19;315(15):1624–1645.
   PubMed Web of Science ®Google Scholar
• Zakrzewska JM, Wu J, Mon-Williams M, et al. Evaluating the impact of trigeminal neuralgia. Pain. 2017 Jun;158(6):1166–1174.
   PubMed Web of Science ®Google Scholar
• Yang AI, McShane BJ, Hitti FL, et al. Patterns of opioid use in patients with trigeminal neuralgia undergoing neurosurgery. J Neurosurg. 2019 Jan 11; 131(6):1805–1811.
   PubMedGoogle Scholar
• Zakrzewska JM, Wu N, Lee JYK, et al. Characterizing Treatment Utilization Patterns for Trigeminal Neuralgia in the United States. Clin J Pain. 2018 Aug;34(8):691–699.
   PubMedGoogle Scholar
• Schnell S, Marrodan M, Acosta JN, et al. Trigeminal Neuralgia Crisis - Intravenous Phenytoin as Acute Rescue Treatment. Headache. 2020 Nov;60(10):2247–2253.
   PubMedGoogle Scholar
• Ramirez JA, Mendell JR, Warmolts JR, et al. Phenytoin neuropathy: structural changes in the sural nerve. Ann Neurol. 1986 Feb;19(2):162–167.
   PubMed Web of Science ®Google Scholar
• Yoshikawa H, Abe T, Oda Y. Extremely acute phenytoin-induced peripheral neuropathy. Epilepsia. 1999 Apr;40(4):528–529.
   PubMedGoogle Scholar
• Pringsheim T, Marras C. Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev. 2009 Apr 15;2009(2):Cd006996.
   PubMedGoogle Scholar
• Dosenovic S, Jelicic Kadic A, Miljanovic M, et al. Interventions for Neuropathic Pain: An Overview of Systematic Reviews. Anesth Analg. 2017 Aug;125(2):643–652.
   PubMed Web of Science ®Google Scholar
• Lechin F, van der Dijs B, Lechin ME, et al. Pimozide therapy for trigeminal neuralgia. Arch Neurol. 1989 Sep;46(9):960–963.
   PubMedGoogle Scholar
• Elsherbiny NM, Ahmed E, Kader GA, et al. Inhibitory effect of valproate sodium on pain behavior in diabetic mice involves suppression of spinal histone deacetylase 1 and inflammatory mediators. Int Immunopharmacol. 2019 May;70:16–27.
   PubMed Web of Science ®Google Scholar
• Gill D, Derry S, Wiffen PJ, et al. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011 Oct 5;2011(10):Cd009183.
   Google Scholar
• Wiffen PJ, Derry S, Moore RA, et al Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013 Nov 11;2013(11):Cd010567.
   Google Scholar
• Peiris JB, Perera GL, Devendra SV, et al. Sodium valproate in trigeminal neuralgia. Med J Aust. 1980 Sep 6; 2(5):278.
   PubMed Web of Science ®Google Scholar
• Pirapakaran K, Aggarwal A. The use of low-dose sodium valproate in the management of neuropathic pain: illustrative case series. Intern Med J. 2016 Jul;46(7):849–852.
   PubMedGoogle Scholar
• Buzzi MG, Moskowitz MA. The trigemino-vascular system and migraine. Pathol Biol. 1992 Apr;40(4):313–317.
   PubMed Web of Science ®Google Scholar
• Kanai A, Saito M, Hoka S. Subcutaneous sumatriptan for refractory trigeminal neuralgia. Headache. 2006 Apr;46(4):577–582. discussion 83-4.
   PubMed Web of Science ®Google Scholar
• Kanai A, Suzuki A, Osawa S, et al. Sumatriptan alleviates pain in patients with trigeminal neuralgia. Clin J Pain. 2006 Oct;22(8):677–680.
   PubMedGoogle Scholar
• Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia. 1998 Oct;18(8):532–538.
   PubMed Web of Science ®Google Scholar
• Ghanavatian S, Derian AT. StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2021. StatPearls Publishing Copyright ©.
   Google Scholar
• Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology. 1994 Nov;44(11 Suppl 9):S6–10. discussion S10-1.
   PubMed Web of Science ®Google Scholar
• Vilming ST, Lyberg T, Lataste X. Tizanidine in the management of trigeminal neuralgia. Cephalalgia. 1986 Sep;6(3):181–182.
   PubMed Web of Science ®Google Scholar
• Lindström P, Lindblom U. The analgesic effect of tocainide in trigeminal neuralgia. Pain. 1987 Jan;28(1):45–50.
   PubMed Web of Science ®Google Scholar
• Holmes B, Brogden RN, Heel RC, et al. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1983 Aug;26(2):93–123.
   PubMed Web of Science ®Google Scholar
• Morganroth J, Nestico PF, Horowitz LN. A review of the uses and limitations of tocainide–a class IB antiarrhythmic agent. Am Heart J. 1985 Oct;110(4):856–863.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang M, Zhou M, et al. Non-antiepileptic drugs for trigeminal neuralgia. Cochrane Database Syst Rev. 2013 Dec;3(12):Cd004029.
   Google Scholar
• Zakrzewska JM. Medical management of trigeminal neuropathic pains. Expert Opin Pharmacother. 2010 Jun;11(8):1239–1254.
   PubMed Web of Science ®Google Scholar
• Braune S. Evidence-based pharmacotherapy of neuropathic pain syndromes. MMW Fortschr Med. 2004 Dec 9;146(50):49–51.
   PubMedGoogle Scholar
• Park JH, Lee SH, Kim ST. Pharmacologic management of trigeminal nerve injury pain after dental implant surgery. Int J Prosthodont. 2010 Jul-Aug;23(4):342–346.
   PubMedGoogle Scholar
• Hinckley CA, Kuryshev Y, Sers A, et al. Characterization of Vixotrigine, a Broad-Spectrum Voltage-Gated Sodium Channel Blocker. Mol Pharmacol. 2021 Jan;99(1):49–59.
   PubMed Web of Science ®Google Scholar
• Bennett DL, Clark AJ, Huang J, et al. The Role of Voltage-Gated Sodium Channels in Pain Signaling. Physiol Rev. 2019 Apr 1; 99(2):1079–1151.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Barbosa C, Pei Z, et al. Increased Resurgent Sodium Currents in Nav1.8 Contribute to Nociceptive Sensory Neuron Hyperexcitability Associated with Peripheral Neuropathies. J Neurosci. 2019 Feb 20 39(8):1539–1550.
   PubMedGoogle Scholar
• Varrassi G, Hanna M, Macheras G, et al. Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol. Curr Med Res Opin. 2017 Jun;33(6):1165–1173.
   PubMed Web of Science ®Google Scholar
• Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et al. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain. 1997 Nov;73(2):223–230.
   PubMed Web of Science ®Google Scholar
• Rustagi A, Roychoudhury A, Bhutia O, et al. Lamotrigine Versus Pregabalin in the Management of Refractory Trigeminal Neuralgia: A Randomized Open Label Crossover Trial. J Maxillofac Oral Surg. 2014 Dec;13(4):409–418.
   PubMedGoogle Scholar
• Prisco L, Ganau M, Bibotto Z, Trigeminal neuralgia: successful antiepileptic drug combination therapy in three refractory cases. Drug Health Patient Saf. 2011;3:43–45.
   PubMedGoogle Scholar
• Baker KA, Taylor JW, Lilly GE. Treatment of trigeminal neuralgia: use of baclofen in combination with carbamazepine. Clin Pharm. 1985 Jan-Feb;4(1):93–96.
   PubMedGoogle Scholar
• Siniscalchi A, Gallelli L, Avenoso T, et al. Effects of carbamazepine/oxycodone coadministration in the treatment of trigeminal neuralgia. Ann Pharmacother. 2011 Jun;45(6):e33.
   PubMedGoogle Scholar
• Solaro CM, Ferriero G. Refactory Trigeminal Neuralgia successfully treated by combination therapy (Pregabalin plus Lamotrigine). Mult Scler Relat Disord. 2018 Oct;25:165–166.
   PubMed Web of Science ®Google Scholar
• Dunbar J, Versavel M, Zhao Y, et al. Evaluation of the Pharmacokinetic Interaction Between the Voltage- and Use-Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers. Clin Pharmacol Drug Dev. 2020 Jan;9(1):62–73.
   PubMed Web of Science ®Google Scholar
• Lemos L, Flores S, Oliveira P, et al. Gabapentin supplemented with ropivacain block of trigger points improves pain control and quality of life in trigeminal neuralgia patients when compared with gabapentin alone. Clin J Pain. 2008 Jan;24(1):64–75.
   PubMed Web of Science ®Google Scholar
• Lemos L, Fontes R, Flores S, et al. Effectiveness of the association between carbamazepine and peripheral analgesic block with ropivacaine for the treatment of trigeminal neuralgia. J Pain Res. 2010 Oct 25; 3:201–212.
   PubMedGoogle Scholar
• Johns Hopkins University. Trigeminal Neuralgia. 2022 [cited 2022 January 15]. Available from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/trigeminal-neuralgia
   Google Scholar
• Govoni V, Granieri E, Menini C. The history of the tic douloureux: autopathograph of an Italian lawyer who suffered from trigeminal neuralgia from 1803 to 1824. J Hist Neurosci. 1996 Aug;5(2):169–189.
   PubMedGoogle Scholar
• Eboli P, Stone JL, Aydin S, et al. Historical characterization of trigeminal neuralgia. discussion 86-7. Neurosurgery. 2009 Jun;64(6):1183–1186.
   PubMed Web of Science ®Google Scholar
• Theile J, Cummins T, Iannotti FA. Recent Developments Regarding Voltage-Gated Sodium Channel Blockers for the Treatment of Inherited and Acquired Neuropathic Pain Syndromes. Front Pharmacol. 2011 October 04;2:2.
   PubMedGoogle Scholar
• Varrassi G, Yeam CT, Rekatsina M, et al. The expanding role of the COX inhibitor/opioid receptor agonist combination in the management of pain. Drugs. 2020 Sep;80(14):1443–1453.
   PubMed Web of Science ®Google Scholar
• Raffa RB. Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther. 2001 Aug;26(4):257–264.
   PubMed Web of Science ®Google Scholar
• Drugs.com. Drug Interactions Baclofen. 2022 [cited 2022 January 15]. Available from: https://www.drugs.com/drug-interactions/baclofen-with-phenytoin-318-0-1863-0.html
   Google Scholar
• Hwang JH, Ku J. Herbal medicine for the management of idiopathic trigeminal neuralgia: A protocol for a systematic review of controlled trials. Medicine (Baltimore). 2020 Jun 19; 99(25):e20779.
   PubMedGoogle Scholar